This systematic review examines the safety and efficacy of this monoclonal antibody. Methods: MEDLINE and EMBASE databases were searched. Only randomized controlled trials where campath was used as an induction agent with a minimum sample size of 20 patients were included. Studies which did not directly compare campath with another induction agent were excluded. Primary outcomes measured were acute Torin 1 price rejection rate, CMV infection rate, graft and patient survival. Results: Five studies fulfilled the inclusion criteria. Meta-analysis reveals the overall odd ratios for acute rejection, CMV infection and graft survival at 12 months

were 0.65(0.39 to 1.08), 0.69(0.36 to 1.34) and 0.59(0.31 to 1.12) respectively in favour of campath. Further subgroup analysis shown on Figure 1 check details comparing the efficacy between this antibody with antithymocyte globulin(ATG) found that campath is non inferior in the incidence of acute rejection. Summary: This systematic review demonstrates induction of renal transplantation with campath is not inferior to ATG at 12 months. Larger trials with longer study period would be useful to further ascertain its future

as a definitive effective and safe agent in transplantation. SOFUE TADASHI1, INUI MASASHI2, HARA TAIGA1, NISHIJIMA YOKO1, MORIWAKI KUMIKO1, HAYASHIDA YUSHI3, UEDA NOBUFUMI3, NISHIYAMA AKIRA4, KAKEHI YOSHIYUKI3, KOHNO MASAKAZU1 1Division of Nephrology and Dialysis, Department of CardioRenal and Cerebrovascular Medicine, Kagawa University, Kagawa, Japan; 2Department of Urology, Tokyo Women’s Medical University Yachiyo Medical Center, Chiba, Japan; 3Department of Urology, Kagawa University, Kagawa, Japan; 4Department of Pharmacology, Kagawa University, Kagawa, Japan Introduction: Post-transplant hyperuricemia (PTHU), defined as serum uric acid (UA) concentration ≥7.0 mg/dl or treatment with conventional treatment, reduces

long-term allograft survival in kidney transplant recipients. Febuxostat, a new non-purine selective xanthine oxidase inhibitor, is well tolerated in patients with moderate renal impairment. However, its efficacy and safety Celecoxib in kidney recipients with PTHU is unclear. We therefore assessed the efficacy and safety of febuxostat in stable kidney transplant recipients with PTHU. Methods: Of 93 adult stable kidney transplant recipients, 51 were diagnosed with PTHU and 42 were not (NPTHU group). Of the 51 patients with PTHU, 26 were treated with febuxostat (FX group) and 25 were not (NFX group), at the discretion of each attending physician. One-year changes in serum UA concentrations, rates of achievement of target UA. Results: The FX group showed significantly greater decreases in serum UA (−2.0 ± 1.1 vs. 0.0 ± 0.8 mg/dl/year, p < 0.01) and tended to show a higher rate of achievement of target UA level (50% vs. 24%: odds ratio = 3.17 [95% confidential interval = 0.96−10.5], p = 0.08) than the NFX group.